Preclinical and clinical results regarding the effects of a plant-based antidiabetic formulation versus well established antidiabetic molecules
| Autor: | Claudia Maria GuŢu, Anca Ungurianu, Denisa Marginǎ, Constantin Ionescu-Tȋrgovişte, Oana Cristina Seremet, Elvira Gagniuc, Rucsandra Dǎnciulescu-Miulescu, Octavian Tudor Olaru, Daniela Grǎdinaru |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Blood Glucose Male Antioxidant medicine.medical_treatment Pharmacology medicine.disease_cause law.invention Diabetes Mellitus Experimental 03 medical and health sciences Magnoliopsida 0302 clinical medicine Lipid oxidation Glycation law Diabetes mellitus medicine Animals Humans Hypoglycemic Agents Gliclazide Rats Wistar Aged Flavonoids business.industry Plant Extracts Brain Polyphenols Middle Aged medicine.disease Metformin Oxidative Stress 030104 developmental biology Diabetes Mellitus Type 2 Liver 030220 oncology & carcinogenesis Fruit Female Phytotherapy business Oxidative stress medicine.drug |
| Zdroj: | Pharmacological research. 150 |
| ISSN: | 1096-1186 |
| Popis: | Diabetes mellitus (DM) is a complex syndrome with debilitating long-term complications, comprising alterations of carbohydrate, protein and lipid metabolisms, along increased oxidative stress and chronic low-grade inflammation. Diet management and plant-based formulations can improve the metabolic status of patients, being used as adjuvants of classic antidiabetic therapy. The purpose of our study was to evaluate the impact of a plant-based antidiabetic formulation (PBAF), containing Vaccinium myrtillus, Ribes nigrum, Rosa canina and Capsicum annuum, on the increased oxidative burden found in diabetes mellitus, comparing it with the effects of metformin and gliclazide. Firstly, we characterized the individual plant-derived components of this formulation and also assessed their in vitro radical scavenging capacity. We devised a preclinical study protocol to examine the impact of the PBAF, along metformin and gliclazide, on tissue histology as well as on the redox status of tissue, mitochondria, serum and serum lipoproteins of alloxan-induced diabetic Wistar rats. Subsequently, we assessed their long-term impact on the redox status of serum and isolated serum lipoproteins of type 2 DM (T2DM) patients, taking into consideration their cardiometabolic profile. In the preclinical stage, we found that PBAF was able to enhance total serum antioxidant defense, while metformin yielded the best results regarding the advanced glycation and protein/lipid oxidation of serum and of serum lipoproteins. The latter also improved overall serum redox status and HDL redox function. Also, antidiabetic treatment seemed to increase mitochondrial redox activity, without overturning overall tissue redox balance. Histologically, liver and brain tissues of treated diabetic rats were fairly similar to those of non-diabetic rats. In T2DM patients, the most striking results involved the effects on serum lipoproteins. The tested PBAF exerted protective antioxidant effects on low-density and, especially, on high density lipoproteins. We conclude that this formulation might constitute a good addition to the well-established pharmacological approach of DM, contributing to the reduction of overall oxidative burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect